Yana G Najjar1, Maneka Puligandla2, Sandra J Lee2, John M Kirkwood1. 1. Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: The pivotal E1684, E1690, E1694, and E2696 trials of adjuvant high-dose interferon-α (HDI) enrolled nearly 2000 patients, and established HDI as the standard of care in adjuvant therapy for patients with resected high-risk melanoma. Herein, the authors present an updated analysis of these 4 trials. METHODS: Survival and disease status were updated in September 2016. These data represent a median follow-up of 17.9 years for the E1684 trial, 12.2 years for the E1690 trial, 16.0 years for the E1694 trial, and 16.5 years for the E2696 trial. RESULTS: The current analysis confirmed the benefit to recurrence-free survival (RFS) of HDI in the E1684 trial at a median follow-up of 17.9 years. The RFS benefit in the E1694 trial remained evident at a median follow-up of 16 years. Furthermore, the results of the current study confirmed the RFS benefit of adjuvant HDI compared with observation in a pooled analysis of the E1684 and E1690 trials. No overall survival benefit was apparent in this pooled analysis. Updated results for the E1690 and E2696 trials did not differ from those previously reported. In addition, to the authors' knowledge, the current study is the first to report a significant difference in melanoma-specific survival (MSS) between patients treated with HDI compared with the ganglioside GM2/keyhole limpet hemocyanin (GMK) vaccine in the E1694 trial. CONCLUSIONS: In patients with resected high-risk melanoma, adjuvant HDI demonstrated improved RFS in the E1684 and E1694 trials, and improved MSS in a pooled analysis of HDI in the E1694 trial. To the authors' knowledge, these findings represent the most mature level of evidence for the benefit of HDI with respect to RFS and MSS. HDI is the only approved adjuvant treatment for which there are data available in patients with resected stage IIB/IIC melanoma, and remains a reasonable treatment option in this population.
BACKGROUND: The pivotal E1684, E1690, E1694, and E2696 trials of adjuvant high-dose interferon-α (HDI) enrolled nearly 2000 patients, and established HDI as the standard of care in adjuvant therapy for patients with resected high-risk melanoma. Herein, the authors present an updated analysis of these 4 trials. METHODS: Survival and disease status were updated in September 2016. These data represent a median follow-up of 17.9 years for the E1684 trial, 12.2 years for the E1690 trial, 16.0 years for the E1694 trial, and 16.5 years for the E2696 trial. RESULTS: The current analysis confirmed the benefit to recurrence-free survival (RFS) of HDI in the E1684 trial at a median follow-up of 17.9 years. The RFS benefit in the E1694 trial remained evident at a median follow-up of 16 years. Furthermore, the results of the current study confirmed the RFS benefit of adjuvant HDI compared with observation in a pooled analysis of the E1684 and E1690 trials. No overall survival benefit was apparent in this pooled analysis. Updated results for the E1690 and E2696 trials did not differ from those previously reported. In addition, to the authors' knowledge, the current study is the first to report a significant difference in melanoma-specific survival (MSS) between patients treated with HDI compared with the ganglioside GM2/keyhole limpet hemocyanin (GMK) vaccine in the E1694 trial. CONCLUSIONS: In patients with resected high-risk melanoma, adjuvant HDI demonstrated improved RFS in the E1684 and E1694 trials, and improved MSS in a pooled analysis of HDI in the E1694 trial. To the authors' knowledge, these findings represent the most mature level of evidence for the benefit of HDI with respect to RFS and MSS. HDI is the only approved adjuvant treatment for which there are data available in patients with resected stage IIB/IIC melanoma, and remains a reasonable treatment option in this population.
Authors: Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert Journal: N Engl J Med Date: 2018-04-15 Impact factor: 91.245
Authors: Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Cyril Konto; Axel Hoos; Veerle de Pril; Ravichandra Karra Gurunath; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori Journal: Lancet Oncol Date: 2015-03-31 Impact factor: 41.316
Authors: J M Kirkwood; J Ibrahim; D H Lawson; M B Atkins; S S Agarwala; K Collins; R Mascari; D M Morrissey; P B Chapman Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Natalie J Ives; Stefan Suciu; Alexander M M Eggermont; John Kirkwood; Paul Lorigan; Svetomir N Markovic; Claus Garbe; Keith Wheatley Journal: Eur J Cancer Date: 2017-07-07 Impact factor: 9.162
Authors: J M Kirkwood; J G Ibrahim; V K Sondak; J Richards; L E Flaherty; M S Ernstoff; T J Smith; U Rao; M Steele; R H Blum Journal: J Clin Oncol Date: 2000-06 Impact factor: 44.544
Authors: J M Kirkwood; J G Ibrahim; J A Sosman; V K Sondak; S S Agarwala; M S Ernstoff; U Rao Journal: J Clin Oncol Date: 2001-05-01 Impact factor: 44.544
Authors: John M Kirkwood; Judith Manola; Joseph Ibrahim; Vernon Sondak; Marc S Ernstoff; Uma Rao Journal: Clin Cancer Res Date: 2004-03-01 Impact factor: 12.531
Authors: Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood Journal: N Engl J Med Date: 2017-09-10 Impact factor: 91.245
Authors: Jeffrey E Gershenwald; Richard A Scolyer; Kenneth R Hess; Vernon K Sondak; Georgina V Long; Merrick I Ross; Alexander J Lazar; Mark B Faries; John M Kirkwood; Grant A McArthur; Lauren E Haydu; Alexander M M Eggermont; Keith T Flaherty; Charles M Balch; John F Thompson Journal: CA Cancer J Clin Date: 2017-10-13 Impact factor: 508.702
Authors: Vishal Navani; Moira C Graves; Hiren Mandaliya; Martin Hong; Andre van der Westhuizen; Jennifer Martin; Nikola A Bowden Journal: Cancer Treat Res Date: 2022
Authors: Yana G Najjar; Dustin McCurry; Huang Lin; Yan Lin; Yan Zang; Diwakar Davar; Arivarasan Karunamurthy; Joseph J Drabick; Rogerio I Neves; Lisa H Butterfield; Marc S Ernstoff; Igor Puzanov; Joseph J Skitzki; Jennifer Bordeaux; IlaSri B Summit; Jehovana O Bender; Ju Young Kim; Beiru Chen; Ghanashyam Sarikonda; Anil Pahuja; Jennifer Tsau; Zeni Alfonso; Christian Laing; James F Pingpank; Matthew P Holtzman; Cindy Sander; Amy Rose; Hassane M Zarour; John M Kirkwood; Ahmad A Tarhini Journal: Clin Cancer Res Date: 2021-03-22 Impact factor: 13.801
Authors: Arjun Khunger; Erin Piazza; Sarah Warren; Thomas H Smith; Xing Ren; Andrew White; Nathan Elliott; Alessandra Cesano; Joseph M Beechem; John M Kirkwood; Ahmad A Tarhini Journal: PLoS One Date: 2021-01-11 Impact factor: 3.240